Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$35.41 USD

35.41
135,485

-0.22 (-0.62%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $35.43 +0.02 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Evolus (EOLS) delivered earnings and revenue surprises of -166.67% and -16.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

by Zacks Equity Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Surmodics Stock?

by Zacks Equity Research

Investors need to pay close attention to SRDX stock based on the movements in the options market lately.

Zacks Equity Research

SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

by Zacks Equity Research

Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.

Zacks Equity Research

SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of -116.67% and 8.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System

by Zacks Equity Research

Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.

Zacks Equity Research

Here's Why You Should Retain Surmodics Stock in Your Portfolio Now

by Zacks Equity Research

SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.

Zacks Equity Research

SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge

by Zacks Equity Research

The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.

Zacks Equity Research

SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up

by Zacks Equity Research

Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.

Zacks Equity Research

Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 50% and 10.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Add Surmodics Stock to Your Portfolio Now

by Zacks Equity Research

SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.

Zacks Equity Research

After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)

by Zacks Equity Research

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Best Momentum Stocks to Buy for January 3rd

by Zacks Equity Research

SRDX and CWAN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.

Zacks Equity Research

New Strong Buy Stocks for January 3rd

by Zacks Equity Research

UAA, BRBR, RBA, SRDX and CTRA have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.

Zacks Equity Research

Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?

by Zacks Equity Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down

by Zacks Equity Research

SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

Zacks Equity Research

SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 51.85% and 8.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 8.37% and 2.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SRDX Stock Down Despite FDA Clearance for Pounce XL System

by Zacks Equity Research

Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.